Related Experiment Videos
Antitumor activity in the acridine series
Journal De Pharmacie De Belgique
|January 1, 1989
Summary
The acridine derivative DAMSA demonstrated significant antitumor activity in mouse leukemias and moderate efficacy against the M5076 reticulosarcoma. While generally well-tolerated at 100 mg/kg, higher doses showed systemic toxicity.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Acridine derivatives are investigated for their potential anticancer properties.
- N-[4'-(9-acridinylamino)-3'-methoxyphenyl]-methanesulfonamide analogs were synthesized and evaluated.
- Understanding structure-activity relationships is crucial for developing novel chemotherapeutics.
Purpose of the Study:
- To investigate the antitumor effects of three novel acridine derivatives.
- To evaluate the efficacy of these compounds against experimental murine tumors.
- To assess the preliminary toxicity profile of the most promising analog.
Main Methods:
- Synthesis of three acridine derivatives based on a known scaffold.
- In vivo testing of antitumor activity in murine leukemia models.
- Evaluation of efficacy against the M5076 reticulosarcoma solid tumor model.
- Monitoring of animal body weight and observation for systemic toxic effects.
Main Results:
- The 3,6-bis-dimethylamino analog (DAMSA) exhibited significant antitumor activity in murine leukemias.
- DAMSA demonstrated a moderate inhibitory effect on the M5076 reticulosarcoma.
- A dose of 100 mg/kg of DAMSA resulted in acceptable body weight changes in treated mice.
- Systemic toxicity was observed at a higher dose of 200 mg/kg.
Conclusions:
- DAMSA shows promising antitumor potential, particularly in hematological malignancies.
- Further development of acridine analogs could lead to new anticancer agents.
- Dose-dependent toxicity necessitates careful therapeutic window determination for DAMSA and related compounds.